Entrada Therapeutics, Inc., is a pharmaceutical company based in the United States of America. With an ESG risk rating score of 26.0, the company is classified as having medium risk. Entrada Therapeutics is focused on revolutionizing patient lives through the development of a new class of medicines that target intracellular pathways previously considered inaccessible. Using their innovative Endosomal Escape Vehicle (EEV™)-therapeutics, they aim to enhance the delivery of a wide range of treatment options to various organs and tissues, ultimately improving therapeutic outcomes. Their pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.